コーパス検索結果(共起頻度の集計）
検索語: prove
ヒット件数: 1000
| 一般的な頻出語を「文章内」のリストから除外しています |
| 2語前 |
1語前 |
|
1語後 |
2語後 |
|
文章内 |
| with |
53 |
has |
148 |
|
to |
255 |
be |
225 |
|
patients |
130 |
| and |
36 |
have |
65 |
|
that |
75 |
in |
71 |
|
useful |
89 |
| has |
32 |
may |
59 |
|
useful |
60 |
for |
66 |
|
effective |
69 |
| of |
23 |
biopsy |
56 |
|
the |
47 |
to |
48 |
|
disease |
67 |
| it |
21 |
been |
49 |
|
difficult |
37 |
the |
40 |
|
however |
65 |
| have |
21 |
we |
28 |
|
challenging |
29 |
and |
22 |
|
clinical |
62 |
| this |
17 |
to |
26 |
|
a |
25 |
challenging |
13 |
|
biopsy |
59 |
| that |
16 |
was |
24 |
|
by |
13 |
of |
12 |
|
study |
58 |
| the |
14 |
also |
23 |
|
beneficial |
12 |
concept |
8 |
|
based |
57 |
| these |
10 |
and |
23 |
|
effective |
12 |
allergy |
8 |
|
challenging |
56 |
| not |
10 |
could |
21 |
|
acute |
10 |
effective |
8 |
|
cells |
56 |
| are |
8 |
histologically |
16 |
|
or |
10 |
as |
8 |
|
cancer |
51 |
| cells |
8 |
is |
14 |
|
in |
9 |
a |
7 |
|
difficult |
50 |
| which |
7 |
with |
13 |
|
elusive |
9 |
have |
7 |
|
high |
48 |
| method |
7 |
a |
12 |
|
for |
9 |
useful |
6 |
|
cell |
46 |
| model |
7 |
challenge |
11 |
|
this |
8 |
rejection |
6 |
|
other |
42 |
| is |
7 |
should |
10 |
|
valuable |
7 |
more |
4 |
|
protein |
40 |
| had |
7 |
will |
10 |
|
their |
7 |
this |
4 |
|
treatment |
40 |
| was |
7 |
that |
8 |
|
food |
7 |
due |
4 |
|
using |
38 |
| our |
6 |
not |
8 |
|
efficacious |
7 |
potential |
4 |
|
approach |
38 |
| data |
6 |
of |
7 |
|
probable |
6 |
existence |
4 |
|
due |
36 |
| may |
5 |
results |
7 |
|
its |
6 |
cancer |
4 |
|
data |
36 |
| a |
5 |
are |
6 |
|
and |
5 |
value |
4 |
|
development |
35 |
| in |
5 |
culture |
6 |
|
highly |
5 |
suspected |
4 |
|
years |
35 |
| approach |
5 |
study |
6 |
|
as |
4 |
positive |
3 |
|
imaging |
33 |
| for |
5 |
which |
6 |
|
an |
4 |
disease |
3 |
|
therapy |
33 |
| molecules |
4 |
be |
5 |
|
more |
4 |
major |
3 |
|
studies |
33 |
| models |
4 |
no |
4 |
|
successful |
3 |
mediated |
3 |
|
no |
32 |
| 1 |
4 |
cells |
4 |
|
essential |
3 |
powerful |
3 |
|
highly |
32 |
| system |
4 |
might |
4 |
|
nafld |
3 |
were |
3 |
|
results |
31 |
| been |
4 |
thus |
4 |
|
ige |
3 |
even |
3 |
|
new |
31 |
| we |
4 |
approach |
4 |
|
general |
3 |
lrti |
3 |
|
genetic |
31 |
| results |
3 |
method |
4 |
|
disappointing |
3 |
difficult |
3 |
|
model |
31 |
| interactions |
3 |
clearly |
3 |
|
advantageous |
3 |
they |
3 |
|
method |
30 |
| yet |
3 |
however |
3 |
|
very |
3 |
with |
3 |
|
two |
30 |
| materials |
3 |
were |
3 |
|
ineffective |
3 |
acute |
3 |
|
s |
29 |
| can |
3 |
only |
3 |
|
recurrent |
3 |
clinical |
3 |
|
although |
28 |
| methodology |
3 |
histopathologically |
3 |
|
particularly |
3 |
versatile |
2 |
|
associated |
28 |
| on |
3 |
experimentally |
3 |
|
invasive |
3 |
modulo |
2 |
|
use |
28 |
| plants |
3 |
further |
3 |
|
even |
2 |
applicability |
2 |
|
models |
28 |
| were |
3 |
pathologically |
3 |
|
sufficiently |
2 |
it |
2 |
|
important |
27 |
| patients |
3 |
or |
3 |
|
treatments |
2 |
formation |
2 |
|
used |
27 |
| could |
3 |
the |
3 |
|
significant |
2 |
exhibit |
2 |
|
all |
27 |
| resolution |
3 |
definitively |
3 |
|
safe |
2 |
except |
2 |
|
time |
27 |
| or |
2 |
formally |
3 |
|
quite |
2 |
therapies |
2 |
|
age |
27 |
| information |
2 |
methodology |
3 |
|
experimentally |
2 |
by |
2 |
|
both |
26 |
| vaccines |
2 |
pathology |
3 |
|
peanut |
2 |
obligate |
2 |
|
well |
26 |
| t |
2 |
tests |
2 |
|
appendicitis |
2 |
improve |
2 |
|
function |
26 |
| technology |
2 |
metastasis |
2 |
|
safer |
2 |
cell |
2 |
|
human |
26 |
| findings |
2 |
clinically |
2 |
|
adequate |
2 |
on |
2 |
|
positive |
25 |
| however |
2 |
analysis |
2 |
|
with |
2 |
sensitive |
2 |
|
c |
25 |
| antibodies |
2 |
assays |
2 |
|
decisive |
2 |
at |
2 |
|
n |
25 |
| likely |
2 |
invasively |
2 |
|
hfpef |
2 |
against |
2 |
|
therapeutic |
24 |
| 2 |
2 |
its |
2 |
|
sufficient |
2 |
principle |
2 |
|
specific |
24 |
| properties |
2 |
technology |
2 |
|
clinically |
2 |
beneficial |
2 |
|
complex |
24 |
| tumors |
2 |
can |
2 |
|
chronic |
2 |
is |
2 |
|
response |
24 |
| amides |
2 |
microbiologically |
2 |
|
extremely |
2 |
valuable |
2 |
|
efficient |
24 |
| individuals |
2 |
2 |
2 |
|
important |
2 |
not |
2 |
|
analysis |
24 |
| vitro |
2 |
data |
2 |
|
role |
2 |
median |
2 |
|
first |
24 |
| tool |
2 |
never |
2 |
|
pivotal |
2 |
diagnosis |
2 |
|
activity |
24 |
| test |
2 |
far |
2 |
|
problematic |
2 |
so |
2 |
|
molecular |
23 |
| ms |
2 |
if |
2 |
|
both |
2 |
significant |
2 |
|
gene |
23 |
| all |
2 |
experiments |
2 |
|
pathogenic |
2 |
ability |
2 |
|
significant |
23 |
| agents |
2 |
for |
2 |
|
invaluable |
2 |
because |
2 |
|
under |
22 |
| antibiotics |
2 |
work |
2 |
|
capable |
2 |
importance |
2 |
|
10 |
22 |
| cannot |
2 |
they |
2 |
|
cases |
2 |
based |
2 |
|
during |
22 |
| an |
2 |
as |
2 |
|
rejection |
2 |
potency |
2 |
|
strategy |
22 |
| environment |
2 |
reaction |
2 |
|
possible |
2 |
that |
2 |
|
suspected |
22 |
| spectroscopy |
2 |
ultimately |
2 |
|
these |
2 |
breast |
2 |
|
structure |
21 |
| treatment |
2 |
models |
2 |
|
efficient |
2 |
important |
2 |
|
challenge |
21 |
| 3 |
2 |
dynamics |
2 |
|
stage |
2 |
tumors |
2 |
|
against |
21 |
| coa |
2 |
personnel |
1 |
|
relevant |
2 |
its |
2 |
|
effects |
21 |
| application |
2 |
variants |
1 |
|
fatal |
2 |
we |
2 |
|
drug |
21 |
| sequencing |
2 |
chitosan |
1 |
|
independent |
2 |
inhibit |
2 |
|
included |
21 |
| water |
2 |
loci |
1 |
|
skin |
2 |
presence |
2 |
|
low |
21 |
| analysis |
2 |
smaa |
1 |
|
strong |
1 |
cancers |
2 |
|
different |
20 |
| activity |
2 |
effecthas |
1 |
|
her2 |
1 |
cost |
1 |
|
tool |
20 |
| calculations |
2 |
phenomenon |
1 |
|
n1 |
1 |
precise |
1 |
|
understanding |
20 |
| ligands |
2 |
sonographically |
1 |
|
carcinoma |
1 |
disruption |
1 |
|
food |
20 |
| function |
2 |
rarely |
1 |
|
focal |
1 |
challenge |
1 |
|
thus |
20 |
| diversity |
2 |
impairments |
1 |
|
technically |
1 |
when |
1 |
|
because |
20 |
| so |
2 |
ela |
1 |
|
better |
1 |
enantiomer |
1 |
|
cases |
20 |
| theory |
2 |
mnr |
1 |
|
exceptionally |
1 |
efficacious |
1 |
|
vitro |
20 |
| they |
2 |
devices |
1 |
|
indication |
1 |
biased |
1 |
|
valuable |
19 |
| developed |
2 |
purposes |
1 |
|
ferroelectricity |
1 |
light |
1 |
|
materials |
19 |
| one |
2 |
neither |
1 |
|
using |
1 |
nodes |
1 |
|
binding |
19 |
| inhibitors |
2 |
che |
1 |
|
suscc |
1 |
isolated |
1 |
|
potential |
19 |
| imaging |
2 |
cytokinesis |
1 |
|
uti |
1 |
segmental |
1 |
|
detection |
19 |
| advanced |
2 |
132 |
1 |
|
ubiquitously |
1 |
than |
1 |
|
compared |
19 |
| transfer |
2 |
89 |
1 |
|
unresolvable |
1 |
modified |
1 |
|
beneficial |
19 |
| proposed |
2 |
yet |
1 |
|
pmn |
1 |
informative |
1 |
|
months |
19 |
| protocol |
2 |
need |
1 |
|
fundamental |
1 |
elemental |
1 |
|
methods |
19 |
| outcomes |
2 |
hcd |
1 |
|
molecular |
1 |
353 |
1 |
|
powerful |
19 |
| classified |
2 |
assembly |
1 |
|
nor |
1 |
play |
1 |
|
chemical |
19 |
| diagnosed |
2 |
chemotherapy |
1 |
|
phononic |
1 |
modulation |
1 |
|
lesion |
19 |
| given |
2 |
qpcr |
1 |
|
lifesaving |
1 |
allergic |
1 |
|
properties |
18 |
| proteins |
2 |
theoretically |
1 |
|
hcc |
1 |
method |
1 |
|
conditions |
18 |
| be |
2 |
hilpda |
1 |
|
histologic |
1 |
which |
1 |
|
control |
18 |
| platforms |
2 |
subfamilies |
1 |
|
renal |
1 |
prototyping |
1 |
|
through |
18 |
| approaches |
2 |
vit |
1 |
|
robust |
1 |
s |
1 |
|
p |
18 |
| needed |
2 |
targeting |
1 |
|
cost |
1 |
forefathers |
1 |
|
over |
18 |
| detection |
2 |
agents |
1 |
|
excellent |
1 |
without |
1 |
|
targeting |
18 |
| vaccine |
2 |
investigation |
1 |
|
pneumococcal |
1 |
among |
1 |
|
one |
18 |
| will |
2 |
generally |
1 |
|
feasible |
1 |
fcc |
1 |
|
large |
18 |
| patient |
2 |
pcr |
1 |
|
cirrhosis |
1 |
reduce |
1 |
|
non |
18 |
| immunotherapy |
2 |
remodelling |
1 |
|
targets |
1 |
our |
1 |
|
vivo |
18 |
| modalities |
1 |
formulations |
1 |
|
necessary |
1 |
after |
1 |
|
very |
18 |
| interest |
1 |
around |
1 |
|
presence |
1 |
concepts |
1 |
|
systems |
18 |
| saddles |
1 |
therapy |
1 |
|
crucial |
1 |
refute |
1 |
|
resolution |
18 |
| methodologies |
1 |
apn |
1 |
|
strategy |
1 |
crystal |
1 |
|
virus |
18 |
| gaps |
1 |
industry |
1 |
|
p |
1 |
therapy |
1 |
|
proven |
18 |
| synergy |
1 |
without |
1 |
|
ecd |
1 |
perls |
1 |
|
system |
18 |
| aggregation |
1 |
beads |
1 |
|
record |
1 |
recombinant |
1 |
|
dna |
18 |
| employed |
1 |
5 |
1 |
|
clinical |
1 |
findings |
1 |
|
ecd |
18 |
| transplantation |
1 |
angiographically |
1 |
|
natural |
1 |
viral |
1 |
|
group |
17 |
| printing |
1 |
processes |
1 |
|
neurohormonal |
1 |
despite |
1 |
|
functional |
17 |
| impact |
1 |
statistically |
1 |
|
locally |
1 |
radiologically |
1 |
|
t |
17 |
| toxicity |
1 |
technique |
1 |
|
technique |
1 |
find |
1 |
|
acute |
17 |
| strategy |
1 |
objectively |
1 |
|
every |
1 |
namely |
1 |
|
only |
17 |
| brain |
1 |
now |
1 |
|
surprisingly |
1 |
ia |
1 |
|
genes |
17 |
| protective |
1 |
bispecific |
1 |
|
cardiovascular |
1 |
l |
1 |
|
role |
17 |
| initial |
1 |
stimulation |
1 |
|
secretion |
1 |
phenomenon |
1 |
|
outcomes |
17 |
| grafting |
1 |
strain |
1 |
|
optimal |
1 |
malariae |
1 |
|
mediated |
17 |
| stress |
1 |
go |
1 |
|
stable |
1 |
contribution |
1 |
|
samples |
17 |
| observed |
1 |
samples |
1 |
|
causal |
1 |
images |
1 |
|
further |
17 |
| electrodes |
1 |
complex |
1 |
|
resectable |
1 |
scaffolds |
1 |
|
range |
17 |
| polymers |
1 |
rates |
1 |
|
equal |
1 |
q |
1 |
|
histologically |
17 |
| 367 |
1 |
attenuation |
1 |
|
efficacy |
1 |
successful |
1 |
|
levels |
17 |
| energies |
1 |
unambiguously |
1 |
|
clustering |
1 |
advanced |
1 |
|
reaction |
16 |
| dimensions |
1 |
genetically |
1 |
|
empd |
1 |
component |
1 |
|
progression |
16 |
| changes |
1 |
cencs |
1 |
|
broadly |
1 |
near |
1 |
|
sample |
16 |
| making |
1 |
resources |
1 |
|
them |
1 |
elusive |
1 |
|
identify |
16 |
| addition |
1 |
component |
1 |
|
model |
1 |
retain |
1 |
|
small |
16 |
| responses |
1 |
valve |
1 |
|
conclusively |
1 |
suspect |
1 |
|
approaches |
16 |
| performance |
1 |
analyses |
1 |
|
qualitatively |
1 |
ischaemic |
1 |
|
promising |
16 |
| loop |
1 |
observations |
1 |
|
myeloma |
1 |
capabilities |
1 |
|
yet |
15 |
| requirement |
1 |
well |
1 |
|
widely |
1 |
connection |
1 |
|
many |
15 |
| moreover |
1 |
donors |
1 |
|
between |
1 |
oesophagogastric |
1 |
|
even |
15 |
| photons |
1 |
reo |
1 |
|
hyporesponsive |
1 |
nuclear |
1 |
|
several |
15 |
| phosphodiesterases |
1 |
state |
1 |
|
malignancy |
1 |
or |
1 |
|
related |
15 |
| subpopulation |
1 |
tools |
1 |
|
fractional |
1 |
approach |
1 |
|
multiple |
15 |
| utilizing |
1 |
detection |
1 |
|
refractory |
1 |
real |
1 |
|
free |
15 |
| complexities |
1 |
modeling |
1 |
|
em |
1 |
bbp1 |
1 |
|
active |
15 |
| image |
1 |
latter |
1 |
|
asos |
1 |
rb |
1 |
|
formation |
15 |
| measures |
1 |
sequences |
1 |
|
additionally |
1 |
relevant |
1 |
|
tumor |
15 |
| drugs |
1 |
mucilage |
1 |
|
macrofilaricide |
1 |
theoretically |
1 |
|
general |
15 |
| regions |
1 |
investigations |
1 |
|
cd30 |
1 |
ish |
1 |
|
future |
15 |
| isolate |
1 |
heretofore |
1 |
|
anabolic |
1 |
ci |
1 |
|
risk |
15 |
| tm |
1 |
studies |
1 |
|
powerful |
1 |
novel |
1 |
|
molecules |
15 |
| likewise |
1 |
molecules |
1 |
|
rccs |
1 |
cast |
1 |
|
early |
15 |
| other |
1 |
genome |
1 |
|
oesophageal |
1 |
experimental |
1 |
|
mechanisms |
15 |
| analytical |
1 |
peptides |
1 |
|
steatosis |
1 |
junctional |
1 |
|
liver |
15 |
| events |
1 |
recently |
1 |
|
bbd |
1 |
nov |
1 |
|
stable |
15 |
| ppe |
1 |
surgically |
1 |
|
curative |
1 |
high |
1 |
|
target |
15 |
| affected |
1 |
adenocarcinoma |
1 |
|
far |
1 |
date |
1 |
|
novel |
14 |
| would |
1 |
s |
1 |
|
cma |
1 |
referred |
1 |
|
inhibitors |
14 |
| tree |
1 |
particular |
1 |
|
unacceptable |
1 |
necessity |
1 |
|
despite |
14 |
| 217 |
1 |
new |
1 |
|
utility |
1 |
dimensionality |
1 |
|
infection |
14 |
| activators |
1 |
agonists |
1 |
|
bile |
1 |
engineered |
1 |
|
into |
14 |
| soils |
1 |
plot |
1 |
|
synergistic |
1 |
some |
1 |
|
biological |
14 |
| hole |
1 |
pollution |
1 |
|
transformative |
1 |
however |
1 |
|
up |
14 |
| gwax |
1 |
theorem |
1 |
|
nafl |
1 |
both |
1 |
|
performed |
14 |
| intensive |
1 |
present |
1 |
|
fast |
1 |
advantageous |
1 |
|
without |
14 |
| akt |
1 |
protein |
1 |
|
vexingly |
1 |
target |
1 |
|
diagnosis |
14 |
| overall |
1 |
too |
1 |
|
benign |
1 |
cells |
1 |
|
18 |
14 |
| sequences |
1 |
14 |
1 |
|
activity |
1 |
selective |
1 |
|
application |
14 |
| 483 |
1 |
calculations |
1 |
|
bacterial |
1 |
facile |
1 |
|
immune |
14 |
| bmi1 |
1 |
system |
1 |
|
theoretically |
1 |
s1 |
1 |
|
proteins |
14 |
| plasma |
1 |
inhibitors |
1 |
|
solid |
1 |
therapeutic |
1 |
|
diseases |
14 |
| investigations |
1 |
protocol |
1 |
|
remarkably |
1 |
selection |
1 |
|
if |
14 |
| tmg |
1 |
coast |
1 |
|
critical |
1 |
kaempferol |
1 |
|
capable |
14 |
| works |
1 |
markers |
1 |
|
sub |
1 |
drive |
1 |
|
identified |
14 |
| research |
1 |
flies |
1 |
|
tuberculosis |
1 |
cure |
1 |
|
complete |
14 |
| under |
1 |
documentation |
1 |
|
popular |
1 |
monophyletic |
1 |
|
17 |
14 |
| view |
1 |
guarana |
1 |
|
limited |
1 |
o |
1 |
|
genome |
13 |
| asparagine |
1 |
strains |
1 |
|
then |
1 |
slcbl10 |
1 |
|
research |
13 |
| represents |
1 |
her2 |
1 |
|
quality |
1 |
hypothesis |
1 |
|
three |
13 |
| matrix |
1 |
several |
1 |
|
variable |
1 |
duct |
1 |
|
applications |
13 |
| tube |
1 |
am |
1 |
|
metastatic |
1 |
from |
1 |
|
12 |
13 |
| phi |
1 |
radiocaine |
1 |
|
c3g |
1 |
was |
1 |
|
efficacious |
13 |
| organisms |
1 |
pc |
1 |
|
aa |
1 |
possibility |
1 |
|
energy |
13 |
| here |
1 |
mostly |
1 |
|
pca |
1 |
critical |
1 |
|
expression |
13 |
| those |
1 |
responses |
1 |
|
pharmacological |
1 |
lesions |
1 |
|
efficacy |
13 |
| cortex |
1 |
rotors |
1 |
|
inert |
1 |
automatically |
1 |
|
h |
13 |
| technologies |
1 |
levels |
1 |
|
attr |
1 |
endophthalmitis |
1 |
|
alternative |
13 |
| probable |
1 |
assay |
1 |
|
so |
1 |
2pg |
1 |
|
vaccine |
13 |
| experimentally |
1 |
dna |
1 |
|
much |
1 |
mp2 |
1 |
|
elusive |
13 |
| phenomenon |
1 |
proposed |
1 |
|
idiopathic |
1 |
approaches |
1 |
|
cohort |
13 |
| inflammatory |
1 |
moiety |
1 |
|
equally |
1 |
stereospecific |
1 |
|
single |
13 |
| ims |
1 |
bepp |
1 |
|
notoriously |
1 |
functional |
1 |
|
some |
13 |
| titration |
1 |
would |
1 |
|
further |
1 |
need |
1 |
|
changes |
13 |
| processes |
1 |
test |
1 |
|
ifd |
1 |
intriguing |
1 |
|
responses |
13 |
| substrates |
1 |
help |
1 |
|
viable |
1 |
data |
1 |
|
lower |
13 |
| srta |
1 |
oxygenation |
1 |
|
plq |
1 |
clonal |
1 |
|
processes |
13 |
| basis |
1 |
by |
1 |
|
association |
1 |
presumed |
1 |
|
trials |
13 |
| etiology |
1 |
lc |
1 |
|
hrls |
1 |
micronization |
1 |
|
developed |
13 |
| filaments |
1 |
dipeptide |
1 |
|
here |
1 |
suggesting |
1 |
|
brain |
12 |
| relationship |
1 |
spectrometry |
1 |
|
serous |
1 |
unique |
1 |
|
likely |
12 |
| regulation |
1 |
bodipy |
1 |
|
affect |
1 |
improvement |
1 |
|
species |
12 |
| necessary |
1 |
10 |
1 |
|
diffuse |
1 |
amyloidosis |
1 |
|
similar |
12 |
| trafficking |
1 |
interventions |
1 |
|
ca |
1 |
t1a |
1 |
|
association |
12 |
| done |
1 |
increased |
1 |
|
ah |
1 |
pathogenicity |
1 |
|
reported |
12 |
| excitations |
1 |
psmad3 |
1 |
|
otherwise |
1 |
provided |
1 |
|
information |
12 |
| robust |
1 |
all |
1 |
|
extracardiac |
1 |
daua |
1 |
|
variants |
12 |
| hyperoxia |
1 |
included |
1 |
|
cellular |
1 |
treatments |
1 |
|
electron |
12 |
| protein |
1 |
adjuvant |
1 |
|
drug |
1 |
capability |
1 |
|
95 |
12 |
| proposes |
1 |
spres |
1 |
|
interesting |
1 |
contain |
1 |
|
dimensional |
12 |
| cd38 |
1 |
curing |
1 |
|
resistant |
1 |
v122i |
1 |
|
13 |
12 |
| ramp |
1 |
unless |
1 |
|
impractical |
1 |
targeted |
1 |
|
experiments |
12 |
| subsequent |
1 |
25 |
1 |
|
recalcitrant |
1 |
changing |
1 |
|
transfer |
12 |
| electrogenic |
1 |
predictions |
1 |
|
gca |
1 |
primary |
1 |
|
consecutive |
12 |
| nemo |
1 |
flp |
1 |
|
slow |
1 |
efficient |
1 |
|
findings |
12 |
| date |
1 |
patients |
1 |
|
mechanisms |
1 |
simplicity |
1 |
|
compounds |
12 |
| sims |
1 |
current |
1 |
|
therapy |
1 |
probable |
1 |
|
number |
12 |
| esmolfe |
1 |
systems |
1 |
|
favorable |
1 |
simulate |
1 |
|
including |
12 |
| spc29 |
1 |
isolation |
1 |
|
glioma |
1 |
hylic |
1 |
|
clinically |
12 |
| mechanism |
1 |
form |
1 |
|
congruences |
1 |
main |
1 |
|
mutations |
12 |
| activities |
1 |
jet |
1 |
|
matrix |
1 |
structural |
1 |
|
15 |
12 |
| cultures |
1 |
structure |
1 |
|
indispensable |
1 |
signaling |
1 |
|
mass |
12 |
| proteomics |
1 |
interface |
1 |
|
benefit |
1 |
iii |
1 |
|
known |
12 |
| cases |
1 |
changes |
1 |
|
it |
1 |
who |
1 |
|
tumors |
12 |
| drying |
1 |
quantitation |
1 |
|
methods |
1 |
electric |
1 |
|
drugs |
12 |
| diseases |
1 |
genes |
1 |
|
nonalcoholic |
1 |
variants |
1 |
|
patient |
12 |
| undistorted |
1 |
accuracy |
1 |
|
testicular |
1 |
accurately |
1 |
|
sensitive |
12 |
| interface |
1 |
step |
1 |
|
intractable |
1 |
barrier |
1 |
|
ms |
12 |
| unlikely |
1 |
9784 |
1 |
|
via |
1 |
actual |
1 |
|
plasma |
12 |
| mutagenesis |
1 |
two |
1 |
|
specificity |
1 |
comparing |
1 |
|
relevant |
12 |
| inhibition |
1 |
nps |
1 |
|
enhancement |
1 |
attainability |
1 |
|
technique |
12 |
| available |
1 |
mutation |
1 |
|
regression |
1 |
invasive |
1 |
|
anti |
12 |
| exploitable |
1 |
wp |
1 |
|
prostate |
1 |
ovarian |
1 |
|
water |
12 |
| aryl |
1 |
summer |
1 |
|
celiac |
1 |
vine |
1 |
|
cancers |
11 |
| autophagy |
1 |
treatment |
1 |
|
cross |
1 |
ipa |
1 |
|
experimentally |
11 |
| stability |
1 |
pca |
1 |
|
positive |
1 |
work |
1 |
|
state |
11 |
| ahmed |
1 |
first |
1 |
|
therapeutically |
1 |
geographical |
1 |
|
dynamics |
11 |
| comparative |
1 |
base |
1 |
|
critically |
1 |
specific |
1 |
|
assembly |
11 |
| k |
1 |
ct |
1 |
|
hiv |
1 |
t |
1 |
|
experimental |
11 |
| sensors |
1 |
signaling |
1 |
|
iliac |
1 |
large |
1 |
|
treatments |
11 |
| spmss |
1 |
photoluminescence |
1 |
|
informative |
1 |
occurrence |
1 |
|
effect |
11 |
| genome |
1 |
undoubtedly |
1 |
|
on |
1 |
self |
1 |
|
impact |
11 |
| used |
1 |
essentially |
1 |
|
neuroendocrine |
1 |
65 |
1 |
|
growth |
11 |
| studies |
1 |
viruses |
1 |
|
breast |
1 |
observing |
1 |
|
concept |
11 |
| engineered |
1 |
type |
1 |
|
not |
1 |
had |
1 |
|
outcome |
11 |
| presenting |
1 |
msi |
1 |
|
analytically |
1 |
promising |
1 |
|
among |
11 |
| editing |
1 |
acts |
1 |
|
scalable |
1 |
appendicitis |
1 |
|
induced |
11 |
| mofs |
1 |
tuberculosis |
1 |
|
nash |
1 |
differ |
1 |
|
e |
11 |
| vivo |
1 |
color |
1 |
|
satisfactory |
1 |
utility |
1 |
|
signaling |
11 |
| enhancers |
1 |
dihydroeugenol |
1 |
|
insensitive |
1 |
susceptible |
1 |
|
overall |
11 |
| trials |
1 |
trial |
1 |
|
endophthalmitis |
1 |
rejections |
1 |
|
conventional |
11 |
| ccl3 |
1 |
strategy |
1 |
|
myelofibrosis |
1 |
over |
1 |
|
higher |
11 |
| design |
1 |
cyclophosphamide |
1 |
|
extraordinarily |
1 |
hhd |
1 |
|
structural |
11 |
| 1beta |
1 |
standard |
1 |
|
sarcoidosis |
1 |
productive |
1 |
|
natural |
11 |
| wolbachia |
1 |
pyreniporphyrin |
1 |
|
iga |
1 |
universal |
1 |
|
dynamic |
11 |
| neutrophils |
1 |
histology |
1 |
|
physiologically |
1 |
these |
1 |
|
rejection |
11 |
| viruses |
1 |
mdct |
1 |
|
igan |
1 |
n |
1 |
|
far |
11 |
| potent |
1 |
result |
1 |
|
cscc |
1 |
hev |
1 |
|
various |
11 |
| n0m0 |
1 |
in |
1 |
|
method |
1 |
increase |
1 |
|
improve |
11 |
| detect |
1 |
likely |
1 |
|
detrimental |
1 |
strong |
1 |
|
allergy |
11 |
| walls |
1 |
had |
1 |
|
malignant |
1 |
world |
1 |
|
design |
11 |
| solid |
1 |
alleles |
1 |
|
helpful |
1 |
respective |
1 |
|
identifying |
11 |
| chemometric |
1 |
analogues |
1 |
|
lm |
1 |
independent |
1 |
|
performance |
11 |
| antigen |
1 |
already |
1 |
|
safety |
1 |
affect |
1 |
|
discovery |
11 |
| based |
1 |
rigorously |
1 |
|
scaffold |
1 |
amr |
1 |
|
treated |
11 |
| toolkit |
1 |
eventually |
1 |
|
rectal |
1 |
steatohepatitis |
1 |
|
culture |
11 |
| chemistry |
1 |
from |
1 |
|
since |
1 |
five |
1 |
|
strategies |
11 |
| allostery |
1 |
tin |
1 |
|
suitable |
1 |
hybrid |
1 |
|
mean |
11 |
| compound |
1 |
lcc |
1 |
|
immune |
1 |
result |
1 |
|
demonstrate |
11 |
| genomic |
1 |
kf |
1 |
|
substantial |
1 |
restricted |
1 |
|
respectively |
11 |
| chia |
1 |
involves |
1 |
|
antagonists |
1 |
elisa |
1 |
|
acid |
11 |
| further |
1 |
derivatives |
1 |
|
viral |
1 |
mcd |
1 |
|
quantification |
11 |
| physiological |
1 |
but |
1 |
|
instrumental |
1 |
give |
1 |
|
o |
11 |
| mice |
1 |
intervention |
1 |
|
treatment |
1 |
fnac |
1 |
|
ct |
11 |
| preorganized |
1 |
unequivocally |
1 |
|
lynch |
1 |
time |
1 |
|
so |
10 |
| authors |
1 |
disiloxanediols |
1 |
|
diagnostically |
1 |
best |
1 |
|
robust |
10 |
| children |
1 |
process |
1 |
|
|
|
efficacy |
1 |
|
identification |
10 |
| disease |
1 |
urine |
1 |
|
|
|
mir |
1 |
|
variety |
10 |
| formulations |
1 |
binding |
1 |
|
|
|
almost |
1 |
|
agents |
10 |
| kpna4 |
1 |
medicinally |
1 |
|
|
|
37 |
1 |
|
since |
10 |
| 6 |
1 |
electrophoresis |
1 |
|
|
|
provide |
1 |
|
limited |
10 |
| linker |
1 |
directly |
1 |
|
|
|
safety |
1 |
|
successful |
10 |
| lung |
1 |
costs |
1 |
|
|
|
orthogonal |
1 |
|
directly |
10 |
| minicomputer |
1 |
cloxacillin |
1 |
|
|
|
mechanical |
1 |
|
dependent |
10 |
| macrophages |
1 |
blood |
1 |
|
|
|
mean |
1 |
|
tested |
10 |
| kras |
1 |
dkk2 |
1 |
|
|
|
nephropathy |
1 |
|
safe |
10 |
| feasible |
1 |
effectively |
1 |
|
|
|
inactive |
1 |
|
generation |
10 |
| capsids |
1 |
effects |
1 |
|
|
|
since |
1 |
|
breast |
10 |
| windows |
1 |
hmscs |
1 |
|
|
|
icu |
1 |
|
evidence |
10 |
| process |
1 |
rdf |
1 |
|
|
|
experiments |
1 |
|
recent |
10 |
| vgcc |
1 |
2016 |
1 |
|
|
|
feasibility |
1 |
|
chronic |
10 |
| pca |
1 |
established |
1 |
|
|
|
effectiveness |
1 |
|
before |
10 |
| ebov |
1 |
|
|
|
|
|
predictors |
1 |
|
organic |
10 |
| game |
1 |
|
|
|
|
|
alloreactive |
1 |
|
source |
10 |
| hybrid |
1 |
|
|
|
|
|
liver |
1 |
|
long |
10 |
| assembly |
1 |
|
|
|
|
|
negative |
1 |
|
interactions |
10 |
| hypothesis |
1 |
|
|
|
|
|
consider |
1 |
|
31 |
10 |
| pb |
1 |
|
|
|
|
|
part |
1 |
|
simple |
10 |
| snps |
1 |
|
|
|
|
|
accommodating |
1 |
|
selective |
10 |
| automated |
1 |
|
|
|
|
|
pneumococcal |
1 |
|
addition |
10 |
| systematically |
1 |
|
|
|
|
|
ultraviolet |
1 |
|
techniques |
10 |
| although |
1 |
|
|
|
|
|
effects |
1 |
|
january |
10 |
| found |
1 |
|
|
|
|
|
about |
1 |
|
diagnostic |
10 |
| review |
1 |
|
|
|
|
|
tram |
1 |
|
quality |
10 |
| proxies |
1 |
|
|
|
|
|
causes |
1 |
|
stage |
10 |
| lesions |
1 |
|
|
|
|
|
general |
1 |
|
direct |
10 |
| reporter |
1 |
|
|
|
|
|
consuming |
1 |
|
test |
10 |
| superoxide |
1 |
|
|
|
|
|
syndrome |
1 |
|
less |
10 |
| interventions |
1 |
|
|
|
|
|
isospec |
1 |
|
standard |
10 |
| tissue |
1 |
|
|
|
|
|
lims |
1 |
|
furthermore |
10 |
| before |
1 |
|
|
|
|
|
|
|
|
beta |
10 |
| northwest |
1 |
|
|
|
|
|
|
|
|
level |
10 |
| differentiation |
1 |
|
|
|
|
|
|
|
|
provide |
10 |
| old |
1 |
|
|
|
|
|
|
|
|
total |
10 |
| to |
1 |
|
|
|
|
|
|
|
|
median |
10 |
| status |
1 |
|
|
|
|
|
|
|
|
established |
10 |
| conditions |
1 |
|
|
|
|
|
|
|
|
peptide |
10 |
| technique |
1 |
|
|
|
|
|
|
|
|
surface |
10 |
| different |
1 |
|
|
|
|
|
|
|
|
ligand |
10 |
| benefit |
1 |
|
|
|
|
|
|
|
|
bacteria |
10 |
| bound |
1 |
|
|
|
|
|
|
|
|
coa |
10 |
| developing |
1 |
|
|
|
|
|
|
|
|
type |
10 |
| acetoxymethyl |
1 |
|
|
|
|
|
|
|
|
children |
10 |
| set |
1 |
|
|
|
|
|
|
|
|
cost |
9 |
| 4a |
1 |
|
|
|
|
|
|
|
|
interventions |
9 |
| consecutive |
1 |
|
|
|
|
|
|
|
|
women |
9 |
| evidence |
1 |
|
|
|
|
|
|
|
|
substrates |
9 |
| trial |
1 |
|
|
|
|
|
|
|
|
negative |
9 |
| arch |
1 |
|
|
|
|
|
|
|
|
often |
9 |
| purification |
1 |
|
|
|
|
|
|
|
|
terms |
9 |
| conception |
1 |
|
|
|
|
|
|
|
|
employed |
9 |
| fnp |
1 |
|
|
|
|
|
|
|
|
targeted |
9 |
| cell |
1 |
|
|
|
|
|
|
|
|
value |
9 |
| numerically |
1 |
|
|
|
|
|
|
|
|
date |
9 |
| incubated |
1 |
|
|
|
|
|
|
|
|
mr |
9 |
| variation |
1 |
|
|
|
|
|
|
|
|
sequencing |
9 |
| surprisingly |
1 |
|
|
|
|
|
|
|
|
major |
9 |
| spain |
1 |
|
|
|
|
|
|
|
|
g |
9 |
| activation |
1 |
|
|
|
|
|
|
|
|
optical |
9 |
| superradiance |
1 |
|
|
|
|
|
|
|
|
activation |
9 |
| lower |
1 |
|
|
|
|
|
|
|
|
reactions |
9 |
| ce |
1 |
|
|
|
|
|
|
|
|
presence |
9 |
| myc |
1 |
|
|
|
|
|
|
|
|
achieving |
9 |
| expression |
1 |
|
|
|
|
|
|
|
|
devices |
9 |
| obtained |
1 |
|
|
|
|
|
|
|
|
now |
9 |
| eyes |
1 |
|
|
|
|
|
|
|
|
full |
9 |
| defined |
1 |
|
|
|
|
|
|
|
|
potent |
9 |
| carboxamide |
1 |
|
|
|
|
|
|
|
|
required |
9 |
| dysfunction |
1 |
|
|
|
|
|
|
|
|
given |
9 |
| targets |
1 |
|
|
|
|
|
|
|
|
f |
9 |
| life |
1 |
|
|
|
|
|
|
|
|
membrane |
9 |
| principle |
1 |
|
|
|
|
|
|
|
|
men |
9 |
| loci |
1 |
|
|
|
|
|
|
|
|
preventing |
9 |
| kit |
1 |
|
|
|
|
|
|
|
|
rates |
9 |
| h |
1 |
|
|
|
|
|
|
|
|
review |
9 |
| recovery |
1 |
|
|
|
|
|
|
|
|
like |
9 |
| calf |
1 |
|
|
|
|
|
|
|
|
selection |
9 |
| work |
1 |
|
|
|
|
|
|
|
|
tools |
9 |
| antibody |
1 |
|
|
|
|
|
|
|
|
possible |
9 |
| staudinger |
1 |
|
|
|
|
|
|
|
|
inflammatory |
9 |
| them |
1 |
|
|
|
|
|
|
|
|
care |
9 |
| stroma |
1 |
|
|
|
|
|
|
|
|
whereas |
9 |
| paradigm |
1 |
|
|
|
|
|
|
|
|
features |
9 |
| oculomotility |
1 |
|
|
|
|
|
|
|
|
process |
9 |
| effects |
1 |
|
|
|
|
|
|
|
|
particularly |
9 |
| diagnosis |
1 |
|
|
|
|
|
|
|
|
il |
9 |
| instability |
1 |
|
|
|
|
|
|
|
|
importance |
9 |
| pathway |
1 |
|
|
|
|
|
|
|
|
show |
9 |
| irrigation |
1 |
|
|
|
|
|
|
|
|
available |
8 |
| rhizosphere |
1 |
|
|
|
|
|
|
|
|
structures |
8 |
| labeled |
1 |
|
|
|
|
|
|
|
|
being |
8 |
| kinases |
1 |
|
|
|
|
|
|
|
|
temperature |
8 |
| mass |
1 |
|
|
|
|
|
|
|
|
containing |
8 |
| from |
1 |
|
|
|
|
|
|
|
|
values |
8 |
| receptors |
1 |
|
|
|
|
|
|
|
|
donor |
8 |
| g |
1 |
|
|
|
|
|
|
|
|
technology |
8 |
| rootstocks |
1 |
|
|
|
|
|
|
|
|
essential |
8 |
| insights |
1 |
|
|
|
|
|
|
|
|
vaccines |
8 |
| tested |
1 |
|
|
|
|
|
|
|
|
tcr |
8 |
| survey |
1 |
|
|
|
|
|
|
|
|
relative |
8 |
| cytometry |
1 |
|
|
|
|
|
|
|
|
states |
8 |
| significantly |
1 |
|
|
|
|
|
|
|
|
nature |
8 |
| bind |
1 |
|
|
|
|
|
|
|
|
obtained |
8 |
| rt |
1 |
|
|
|
|
|
|
|
|
pathways |
8 |
| achievements |
1 |
|
|
|
|
|
|
|
|
proposed |
8 |
| adaptation |
1 |
|
|
|
|
|
|
|
|
trial |
8 |
| enhancements |
1 |
|
|
|
|
|
|
|
|
stress |
8 |
| published |
1 |
|
|
|
|
|
|
|
|
found |
8 |
| 018 |
1 |
|
|
|
|
|
|
|
|
animal |
8 |
| fibers |
1 |
|
|
|
|
|
|
|
|
generated |
8 |
| nanomaterials |
1 |
|
|
|
|
|
|
|
|
need |
8 |
| dry |
1 |
|
|
|
|
|
|
|
|
antibodies |
8 |
| compounds |
1 |
|
|
|
|
|
|
|
|
spectroscopy |
8 |
| malignant |
1 |
|
|
|
|
|
|
|
|
mice |
8 |
| both |
1 |
|
|
|
|
|
|
|
|
magnetic |
8 |
| complexity |
1 |
|
|
|
|
|
|
|
|
dose |
8 |
| nutrients |
1 |
|
|
|
|
|
|
|
|
moreover |
8 |
| scaffold |
1 |
|
|
|
|
|
|
|
|
work |
8 |
| 0 |
1 |
|
|
|
|
|
|
|
|
accurate |
8 |
| gap |
1 |
|
|
|
|
|
|
|
|
order |
8 |
| applications |
1 |
|
|
|
|
|
|
|
|
see |
8 |
| fluctuation |
1 |
|
|
|
|
|
|
|
|
year |
8 |
| 23 |
1 |
|
|
|
|
|
|
|
|
wide |
8 |
| sensor |
1 |
|
|
|
|
|
|
|
|
targets |
8 |
| vineyards |
1 |
|
|
|
|
|
|
|
|
follow |
8 |
| distribution |
1 |
|
|
|
|
|
|
|
|
death |
8 |
| long |
1 |
|
|
|
|
|
|
|
|
antibody |
8 |
| photovoltaic |
1 |
|
|
|
|
|
|
|
|
v |
8 |
| practice |
1 |
|
|
|
|
|
|
|
|
interaction |
8 |
| previously |
1 |
|
|
|
|
|
|
|
|
pathogenic |
8 |
| microenvironment |
1 |
|
|
|
|
|
|
|
|
testing |
8 |
| vegfd |
1 |
|
|
|
|
|
|
|
|
numbers |
8 |
| finally |
1 |
|
|
|
|
|
|
|
|
current |
8 |
| receptor |
1 |
|
|
|
|
|
|
|
|
class |
8 |
| catalytic |
1 |
|
|
|
|
|
|
|
|
2015 |
8 |
| simple |
1 |
|
|
|
|
|
|
|
|
retrospective |
8 |
| deficit |
1 |
|
|
|
|
|
|
|
|
viral |
8 |
| reactions |
1 |
|
|
|
|
|
|
|
|
parameters |
8 |
| convincingly |
1 |
|
|
|
|
|
|
|
|
prospectively |
8 |
| bonded |
1 |
|
|
|
|
|
|
|
|
newly |
8 |
| planar |
1 |
|
|
|
|
|
|
|
|
ci |
8 |
| ideas |
1 |
|
|
|
|
|
|
|
|
probable |
8 |
| nitrate |
1 |
|
|
|
|
|
|
|
|
combined |
8 |
| their |
1 |
|
|
|
|
|
|
|
|
b |
8 |
| generated |
1 |
|
|
|
|
|
|
|
|
health |
8 |
| silver |
1 |
|
|
|
|
|
|
|
|
additional |
8 |
| methods |
1 |
|
|
|
|
|
|
|
|
neural |
8 |
| signaling |
1 |
|
|
|
|
|
|
|
|
detecting |
8 |
| mpt |
1 |
|
|
|
|
|
|
|
|
solution |
8 |
| calorimetry |
1 |
|
|
|
|
|
|
|
|
screening |
8 |
| enso |
1 |
|
|
|
|
|
|
|
|
antigen |
8 |
| treated |
1 |
|
|
|
|
|
|
|
|
efforts |
8 |
| classification |
1 |
|
|
|
|
|
|
|
|
prospective |
8 |
| lineages |
1 |
|
|
|
|
|
|
|
|
2016 |
8 |
| next |
1 |
|
|
|
|
|
|
|
|
microscopy |
8 |
| ni |
1 |
|
|
|
|
|
|
|
|
change |
8 |
| hnf4a |
1 |
|
|
|
|
|
|
|
|
compound |
8 |
| platform |
1 |
|
|
|
|
|
|
|
|
significantly |
8 |
| during |
1 |
|
|
|
|
|
|
|
|
hydrogen |
8 |
| nuclease |
1 |
|
|
|
|
|
|
|
|
suitable |
8 |
| traits |
1 |
|
|
|
|
|
|
|
|
50 |
8 |
| nrf2 |
1 |
|
|
|
|
|
|
|
|
catalyst |
8 |
| enhancement |
1 |
|
|
|
|
|
|
|
|
partial |
8 |
| gd |
1 |
|
|
|
|
|
|
|
|
inhibition |
7 |
| coatings |
1 |
|
|
|
|
|
|
|
|
producing |
7 |
| condition |
1 |
|
|
|
|
|
|
|
|
interest |
7 |
| cfae |
1 |
|
|
|
|
|
|
|
|
transition |
7 |
| clonotypes |
1 |
|
|
|
|
|
|
|
|
versatile |
7 |
| homogeneous |
1 |
|
|
|
|
|
|
|
|
conducted |
7 |
| pet |
1 |
|
|
|
|
|
|
|
|
present |
7 |
| molecular |
1 |
|
|
|
|
|
|
|
|
stability |
7 |
| c3 |
1 |
|
|
|
|
|
|
|
|
sequence |
7 |
| mcl1 |
1 |
|
|
|
|
|
|
|
|
40 |
7 |
| dimension |
1 |
|
|
|
|
|
|
|
|
able |
7 |
| oxides |
1 |
|
|
|
|
|
|
|
|
21 |
7 |
| observations |
1 |
|
|
|
|
|
|
|
|
safety |
7 |
| wild |
1 |
|
|
|
|
|
|
|
|
series |
7 |
| processing |
1 |
|
|
|
|
|
|
|
|
alpha |
7 |
| desi |
1 |
|
|
|
|
|
|
|
|
plants |
7 |
| standard |
1 |
|
|
|
|
|
|
|
|
ability |
7 |
| discovery |
1 |
|
|
|
|
|
|
|
|
phase |
7 |
| volitional |
1 |
|
|
|
|
|
|
|
|
randomized |
7 |
| gi |
1 |
|
|
|
|
|
|
|
|
cm |
7 |
| cochlea |
1 |
|
|
|
|
|
|
|
|
versus |
7 |
| but |
1 |
|
|
|
|
|
|
|
|
improving |
7 |
| development |
1 |
|
|
|
|
|
|
|
|
cardiovascular |
7 |
| feedback |
1 |
|
|
|
|
|
|
|
|
normal |
7 |
| fuzzy |
1 |
|
|
|
|
|
|
|
|
nash |
7 |
| antigens |
1 |
|
|
|
|
|
|
|
|
analyses |
7 |
| fixation |
1 |
|
|
|
|
|
|
|
|
spectrometry |
7 |
| algorithms |
1 |
|
|
|
|
|
|
|
|
form |
7 |
| pivotal |
1 |
|
|
|
|
|
|
|
|
across |
7 |
| bacteria |
1 |
|
|
|
|
|
|
|
|
global |
7 |
| infection |
1 |
|
|
|
|
|
|
|
|
population |
7 |
| fertility |
1 |
|
|
|
|
|
|
|
|
allow |
7 |
| assessment |
1 |
|
|
|
|
|
|
|
|
onset |
7 |
| dia |
1 |
|
|
|
|
|
|
|
|
formula |
7 |
| whether |
1 |
|
|
|
|
|
|
|
|
text |
7 |
| additionally |
1 |
|
|
|
|
|
|
|
|
appendicitis |
7 |
| internal |
1 |
|
|
|
|
|
|
|
|
therapies |
7 |
| phenotypes |
1 |
|
|
|
|
|
|
|
|
field |
7 |
| settings |
1 |
|
|
|
|
|
|
|
|
100 |
7 |
| device |
1 |
|
|
|
|
|
|
|
|
complexes |
7 |
| change |
1 |
|
|
|
|
|
|
|
|
therefore |
7 |
| worsening |
1 |
|
|
|
|
|
|
|
|
recently |
7 |
| 7 |
1 |
|
|
|
|
|
|
|
|
analytical |
7 |
| type |
1 |
|
|
|
|
|
|
|
|
sensitivity |
7 |
| such |
1 |
|
|
|
|
|
|
|
|
needed |
7 |
| gce |
1 |
|
|
|
|
|
|
|
|
specificity |
7 |
| pt |
1 |
|
|
|
|
|
|
|
|
reliable |
7 |
| analyses |
1 |
|
|
|
|
|
|
|
|
complications |
7 |
| sers |
1 |
|
|
|
|
|
|
|
|
production |
7 |
| r17h |
1 |
|
|
|
|
|
|
|
|
throughput |
7 |
| animals |
1 |
|
|
|
|
|
|
|
|
factors |
7 |
| apart |
1 |
|
|
|
|
|
|
|
|
lung |
7 |
| assays |
1 |
|
|
|
|
|
|
|
|
complexity |
7 |
| rcts |
1 |
|
|
|
|
|
|
|
|
guided |
7 |
| tr |
1 |
|
|
|
|
|
|
|
|
distribution |
7 |
| etherification |
1 |
|
|
|
|
|
|
|
|
60 |
7 |
| 178 |
1 |
|
|
|
|
|
|
|
|
16 |
7 |
| focused |
1 |
|
|
|
|
|
|
|
|
25 |
7 |
| hus |
1 |
|
|
|
|
|
|
|
|
derived |
7 |
| s |
1 |
|
|
|
|
|
|
|
|
sufficient |
7 |
| constants |
1 |
|
|
|
|
|
|
|
|
diverse |
7 |
| liver |
1 |
|
|
|
|
|
|
|
|
methodology |
7 |
| adenosine |
1 |
|
|
|
|
|
|
|
|
critical |
7 |
| pharmacology |
1 |
|
|
|
|
|
|
|
|
lrti |
7 |
| emerged |
1 |
|
|
|
|
|
|
|
|
best |
7 |
| inhibitor |
1 |
|
|
|
|
|
|
|
|
term |
7 |
| success |
1 |
|
|
|
|
|
|
|
|
disorders |
7 |
| do |
1 |
|
|
|
|
|
|
|
|
content |
7 |
| educational |
1 |
|
|
|
|
|
|
|
|
products |
7 |
| should |
1 |
|
|
|
|
|
|
|
|
14 |
7 |
| domino |
1 |
|
|
|
|
|
|
|
|
principle |
7 |
| unspecific |
1 |
|
|
|
|
|
|
|
|
infections |
7 |
| engineering |
1 |
|
|
|
|
|
|
|
|
remains |
7 |
| suspected |
1 |
|
|
|
|
|
|
|
|
20 |
7 |
| as |
1 |
|
|
|
|
|
|
|
|
soil |
7 |
| structure |
1 |
|
|
|
|
|
|
|
|
real |
7 |
| capillary |
1 |
|
|
|
|
|
|
|
|
resistant |
7 |
| therapy |
1 |
|
|
|
|
|
|
|
|
upon |
7 |
| difficult |
1 |
|
|
|
|
|
|
|
|
hiv |
7 |
| us |
1 |
|
|
|
|
|
|
|
|
toward |
7 |
| architecture |
1 |
|
|
|
|
|
|
|
|
variation |
7 |
| total |
1 |
|
|
|
|
|
|
|
|
pet |
7 |
| occurs |
1 |
|
|
|
|
|
|
|
|
solid |
7 |
| behaviors |
1 |
|
|
|
|
|
|
|
|
existence |
7 |
| validate |
1 |
|
|
|
|
|
|
|
|
i |
7 |
| whole |
1 |
|
|
|
|
|
|
|
|
receptor |
7 |
| some |
1 |
|
|
|
|
|
|
|
|
treating |
7 |
| formulation |
1 |
|
|
|
|
|
|
|
|
underwent |
7 |
| ibs |
1 |
|
|
|
|
|
|
|
|
hypothesis |
7 |
| observation |
1 |
|
|
|
|
|
|
|
|
common |
6 |
| mos2 |
1 |
|
|
|
|
|
|
|
|
beyond |
6 |
| al |
1 |
|
|
|
|
|
|
|
|
patterns |
6 |
| immunodominance |
1 |
|
|
|
|
|
|
|
|
determining |
6 |
| videography |
1 |
|
|
|
|
|
|
|
|
sequences |
6 |
| stochastic |
1 |
|
|
|
|
|
|
|
|
self |
6 |
| measurements |
1 |
|
|
|
|
|
|
|
|
few |
6 |
|
|
|
|
|
|
|
|
|
|
wall |
6 |
|
|
|
|
|
|
|
|
|
|
achieve |
6 |
|
|
|
|
|
|
|
|
|
|
category |
6 |
|
|
|
|
|
|
|
|
|
|
representations |
6 |
|
|
|
|
|
|
|
|
|
|
traits |
6 |
|
|
|
|
|
|
|
|
|
|
nanoparticles |
6 |
|
|
|
|
|
|
|
|
|
|
relationship |
6 |
|
|
|
|
|
|
|
|
|
|
step |
6 |
|
|
|
|
|
|
|
|
|
|
matrix |
6 |
|
|
|
|
|
|
|
|
|
|
tolerance |
6 |
|
|
|
|
|
|
|
|
|
|
treat |
6 |
|
|
|
|
|
|
|
|
|
|
concentration |
6 |
|
|
|
|
|
|
|
|
|
|
toxicity |
6 |
|
|
|
|
|
|
|
|
|
|
tests |
6 |
|
|
|
|
|
|
|
|
|
|
strong |
6 |
|
|
|
|
|
|
|
|
|
|
case |
6 |
|
|
|
|
|
|
|
|
|
|
better |
6 |
|
|
|
|
|
|
|
|
|
|
increased |
6 |
|
|
|
|
|
|
|
|
|
|
result |
6 |
|
|
|
|
|
|
|
|
|
|
68 |
6 |
|
|
|
|
|
|
|
|
|
|
mechanism |
6 |
|
|
|
|
|
|
|
|
|
|
context |
6 |
|
|
|
|
|
|
|
|
|
|
conjugated |
6 |
|
|
|
|
|
|
|
|
|
|
controlled |
6 |
|
|
|
|
|
|
|
|
|
|
electronic |
6 |
|
|
|
|
|
|
|
|
|
|
ligands |
6 |
|
|
|
|
|
|
|
|
|
|
pd |
6 |
|
|
|
|
|
|
|
|
|
|
modification |
6 |
|
|
|
|
|
|
|
|
|
|
mutation |
6 |
|
|
|
|
|
|
|
|
|
|
regions |
6 |
|
|
|
|
|
|
|
|
|
|
via |
6 |
|
|
|
|
|
|
|
|
|
|
per |
6 |
|
|
|
|
|
|
|
|
|
|
37 |
6 |
|
|
|
|
|
|
|
|
|
|
30 |
6 |
|
|
|
|
|
|
|
|
|
|
advanced |
6 |
|
|
|
|
|
|
|
|
|
|
progressive |
6 |
|
|
|
|
|
|
|
|
|
|
appropriate |
6 |
|
|
|
|
|
|
|
|
|
|
rate |
6 |
|
|
|
|
|
|
|
|
|
|
demonstrated |
6 |
|
|
|
|
|
|
|
|
|
|
bone |
6 |
|
|
|
|
|
|
|
|
|
|
unit |
6 |
|
|
|
|
|
|
|
|
|
|
skin |
6 |
|
|
|
|
|
|
|
|
|
|
point |
6 |
|
|
|
|
|
|
|
|
|
|
reference |
6 |
|
|
|
|
|
|
|
|
|
|
transmission |
6 |
|
|
|
|
|
|
|
|
|
|
m |
6 |
|
|
|
|
|
|
|
|
|
|
alone |
6 |
|
|
|
|
|
|
|
|
|
|
profile |
6 |
|
|
|
|
|
|
|
|
|
|
until |
6 |
|
|
|
|
|
|
|
|
|
|
last |
6 |
|
|
|
|
|
|
|
|
|
|
key |
6 |
|
|
|
|
|
|
|
|
|
|
five |
6 |
|
|
|
|
|
|
|
|
|
|
enrolled |
6 |
|
|
|
|
|
|
|
|
|
|
2014 |
6 |
|
|
|
|
|
|
|
|
|
|
renal |
6 |
|
|
|
|
|
|
|
|
|
|
criteria |
6 |
|
|
|
|
|
|
|
|
|
|
presented |
6 |
|
|
|
|
|
|
|
|
|
|
conclusion |
6 |
|
|
|
|
|
|
|
|
|
|
benefit |
6 |
|
|
|
|
|
|
|
|
|
|
confirmed |
6 |
|
|
|
|
|
|
|
|
|
|
vs |
6 |
|
|
|
|
|
|
|
|
|
|
characterization |
6 |
|
|
|
|
|
|
|
|
|
|
resistance |
6 |
|
|
|
|
|
|
|
|
|
|
migration |
6 |
|
|
|
|
|
|
|
|
|
|
controlling |
6 |
|
|
|
|
|
|
|
|
|
|
component |
6 |
|
|
|
|
|
|
|
|
|
|
therapeutics |
6 |
|
|
|
|
|
|
|
|
|
|
synthesis |
6 |
|
|
|
|
|
|
|
|
|
|
extremely |
6 |
|
|
|
|
|
|
|
|
|
|
second |
6 |
|
|
|
|
|
|
|
|
|
|
measurement |
6 |
|
|
|
|
|
|
|
|
|
|
pre |
6 |
|
|
|
|
|
|
|
|
|
|
same |
6 |
|
|
|
|
|
|
|
|
|
|
individual |
6 |
|
|
|
|
|
|
|
|
|
|
gold |
6 |
|
|
|
|
|
|
|
|
|
|
report |
6 |
|
|
|
|
|
|
|
|
|
|
june |
6 |
|
|
|
|
|
|
|
|
|
|
underlying |
6 |
|
|
|
|
|
|
|
|
|
|
loss |
6 |
|
|
|
|
|
|
|
|
|
|
populations |
6 |
|
|
|
|
|
|
|
|
|
|
components |
6 |
|
|
|
|
|
|
|
|
|
|
optimal |
6 |
|
|
|
|
|
|
|
|
|
|
heart |
6 |
|
|
|
|
|
|
|
|
|
|
defined |
6 |
|
|
|
|
|
|
|
|
|
|
tuberculosis |
6 |
|
|
|
|
|
|
|
|
|
|
metal |
6 |
|
|
|
|
|
|
|
|
|
|
coli |
6 |
|
|
|
|
|
|
|
|
|
|
then |
6 |
|
|
|
|
|
|
|
|
|
|
site |
6 |
|
|
|
|
|
|
|
|
|
|
center |
6 |
|
|
|
|
|
|
|
|
|
|
broadly |
6 |
|
|
|
|
|
|
|
|
|
|
diversity |
6 |
|
|
|
|
|
|
|
|
|
|
allows |
6 |
|
|
|
|
|
|
|
|
|
|
resonance |
6 |
|
|
|
|
|
|
|
|
|
|
additionally |
6 |
|
|
|
|
|
|
|
|
|
|
showed |
6 |
|
|
|
|
|
|
|
|
|
|
native |
6 |
|
|
|
|
|
|
|
|
|
|
base |
6 |
|
|
|
|
|
|
|
|
|
|
following |
6 |
|
|
|
|
|
|
|
|
|
|
period |
6 |
|
|
|
|
|
|
|
|
|
|
evaluated |
6 |
|
|
|
|
|
|
|
|
|
|
considered |
6 |
|
|
|
|
|
|
|
|
|
|
develop |
6 |
|
|
|
|
|
|
|
|
|
|
mrna |
6 |
|
|
|
|
|
|
|
|
|
|
observation |
6 |
|
|
|
|
|
|
|
|
|
|
incidence |
6 |
|
|
|
|
|
|
|
|
|
|
blood |
6 |
|
|
|
|
|
|
|
|
|
|
categories |
6 |
|
|
|
|
|
|
|
|
|
|
invasive |
6 |
|
|
|
|
|
|
|
|
|
|
flow |
6 |
|
|
|
|
|
|
|
|
|
|
male |
6 |
|
|
|
|
|
|
|
|
|
|
assessing |
6 |
|
|
|
|
|
|
|
|
|
|
pathology |
6 |
|
|
|
|
|
|
|
|
|
|
access |
5 |
|
|
|
|
|
|
|
|
|
|
combining |
5 |
|
|
|
|
|
|
|
|
|
|
liquid |
5 |
|
|
|
|
|
|
|
|
|
|
crystal |
5 |
|
|
|
|
|
|
|
|
|
|
precise |
5 |
|
|
|
|
|
|
|
|
|
|
mapping |
5 |
|
|
|
|
|
|
|
|
|
|
selectivity |
5 |
|
|
|
|
|
|
|
|
|
|
certain |
5 |
|
|
|
|
|
|
|
|
|
|
loop |
5 |
|
|
|
|
|
|
|
|
|
|
synergy |
5 |
|
|
|
|
|
|
|
|
|
|
oxygen |
5 |
|
|
|
|
|
|
|
|
|
|
tau |
5 |
|
|
|
|
|
|
|
|
|
|
sites |
5 |
|
|
|
|
|
|
|
|
|
|
metastatic |
5 |
|
|
|
|
|
|
|
|
|
|
elucidating |
5 |
|
|
|
|
|
|
|
|
|
|
nm |
5 |
|
|
|
|
|
|
|
|
|
|
stem |
5 |
|
|
|
|
|
|
|
|
|
|
fl |
5 |
|
|
|
|
|
|
|
|
|
|
management |
5 |
|
|
|
|
|
|
|
|
|
|
coupled |
5 |
|
|
|
|
|
|
|
|
|
|
conversion |
5 |
|
|
|
|
|
|
|
|
|
|
resection |
5 |
|
|
|
|
|
|
|
|
|
|
metastasis |
5 |
|
|
|
|
|
|
|
|
|
|
89 |
5 |
|
|
|
|
|
|
|
|
|
|
initial |
5 |
|
|
|
|
|
|
|
|
|
|
light |
5 |
|
|
|
|
|
|
|
|
|
|
electrochemical |
5 |
|
|
|
|
|
|
|
|
|
|
endogenous |
5 |
|
|
|
|
|
|
|
|
|
|
administration |
5 |
|
|
|
|
|
|
|
|
|
|
surgeons |
5 |
|
|
|
|
|
|
|
|
|
|
metastases |
5 |
|
|
|
|
|
|
|
|
|
|
open |
5 |
|
|
|
|
|
|
|
|
|
|
carcinoma |
5 |
|
|
|
|
|
|
|
|
|
|
diabetes |
5 |
|
|
|
|
|
|
|
|
|
|
amount |
5 |
|
|
|
|
|
|
|
|
|
|
electrodes |
5 |
|
|
|
|
|
|
|
|
|
|
theoretical |
5 |
|
|
|
|
|
|
|
|
|
|
network |
5 |
|
|
|
|
|
|
|
|
|
|
serum |
5 |
|
|
|
|
|
|
|
|
|
|
domain |
5 |
|
|
|
|
|
|
|
|
|
|
theoretically |
5 |
|
|
|
|
|
|
|
|
|
|
ca |
5 |
|
|
|
|
|
|
|
|
|
|
predicting |
5 |
|
|
|
|
|
|
|
|
|
|
especially |
5 |
|
|
|
|
|
|
|
|
|
|
characterize |
5 |
|
|
|
|
|
|
|
|
|
|
causal |
5 |
|
|
|
|
|
|
|
|
|
|
making |
5 |
|
|
|
|
|
|
|
|
|
|
delivery |
5 |
|
|
|
|
|
|
|
|
|
|
cellular |
5 |
|
|
|
|
|
|
|
|
|
|
way |
5 |
|
|
|
|
|
|
|
|
|
|
requirement |
5 |
|
|
|
|
|
|
|
|
|
|
biomarkers |
5 |
|
|
|
|
|
|
|
|
|
|
efficiency |
5 |
|
|
|
|
|
|
|
|
|
|
out |
5 |
|
|
|
|
|
|
|
|
|
|
comparing |
5 |
|
|
|
|
|
|
|
|
|
|
surgical |
5 |
|
|
|
|
|
|
|
|
|
|
ion |
5 |
|
|
|
|
|
|
|
|
|
|
ratio |
5 |
|
|
|
|
|
|
|
|
|
|
possibility |
5 |
|
|
|
|
|
|
|
|
|
|
mesenchymal |
5 |
|
|
|
|
|
|
|
|
|
|
life |
5 |
|
|
|
|
|
|
|
|
|
|
image |
5 |
|
|
|
|
|
|
|
|
|
|
systemic |
5 |
|
|
|
|
|
|
|
|
|
|
understood |
5 |
|
|
|
|
|
|
|
|
|
|
molecule |
5 |
|
|
|
|
|
|
|
|
|
|
x |
5 |
|
|
|
|
|
|
|
|
|
|
receptors |
5 |
|
|
|
|
|
|
|
|
|
|
days |
5 |
|
|
|
|
|
|
|
|
|
|
primary |
5 |
|
|
|
|
|
|
|
|
|
|
fundamental |
5 |
|
|
|
|
|
|
|
|
|
|
improved |
5 |
|
|
|
|
|
|
|
|
|
|
investigate |
5 |
|
|
|
|
|
|
|
|
|
|
about |
5 |
|
|
|
|
|
|
|
|
|
|
importantly |
5 |
|
|
|
|
|
|
|
|
|
|
examination |
5 |
|
|
|
|
|
|
|
|
|
|
individuals |
5 |
|
|
|
|
|
|
|
|
|
|
modifications |
5 |
|
|
|
|
|
|
|
|
|
|
surgery |
5 |
|
|
|
|
|
|
|
|
|
|
line |
5 |
|
|
|
|
|
|
|
|
|
|
iron |
5 |
|
|
|
|
|
|
|
|
|
|
eligible |
5 |
|
|
|
|
|
|
|
|
|
|
evaluation |
5 |
|
|
|
|
|
|
|
|
|
|
central |
5 |
|
|
|
|
|
|
|
|
|
|
plant |
5 |
|
|
|
|
|
|
|
|
|
|
pharmacological |
5 |
|
|
|
|
|
|
|
|
|
|
anticipated |
5 |
|
|
|
|
|
|
|
|
|
|
transformation |
5 |
|
|
|
|
|
|
|
|
|
|
excellent |
5 |
|
|
|
|
|
|
|
|
|
|
preserving |
5 |
|
|
|
|
|
|
|
|
|
|
subjects |
5 |
|
|
|
|
|
|
|
|
|
|
basis |
5 |
|
|
|
|
|
|
|
|
|
|
intensive |
5 |
|
|
|
|
|
|
|
|
|
|
engineering |
5 |
|
|
|
|
|
|
|
|
|
|
suggest |
5 |
|
|
|
|
|
|
|
|
|
|
ad |
5 |
|
|
|
|
|
|
|
|
|
|
factor |
5 |
|
|
|
|
|
|
|
|
|
|
kinase |
5 |
|
|
|
|
|
|
|
|
|
|
interval |
5 |
|
|
|
|
|
|
|
|
|
|
acids |
5 |
|
|
|
|
|
|
|
|
|
|
ia |
5 |
|
|
|
|
|
|
|
|
|
|
hybrid |
5 |
|
|
|
|
|
|
|
|
|
|
recorded |
5 |
|
|
|
|
|
|
|
|
|
|
agent |
5 |
|
|
|
|
|
|
|
|
|
|
post |
5 |
|
|
|
|
|
|
|
|
|
|
necessary |
5 |
|
|
|
|
|
|
|
|
|
|
enzymatic |
5 |
|
|
|
|
|
|
|
|
|
|
environment |
5 |
|
|
|
|
|
|
|
|
|
|
already |
5 |
|
|
|
|
|
|
|
|
|
|
region |
5 |
|
|
|
|
|
|
|
|
|
|
decades |
5 |
|
|
|
|
|
|
|
|
|
|
laboratory |
5 |
|
|
|
|
|
|
|
|
|
|
supported |
5 |
|
|
|
|
|
|
|
|
|
|
effectiveness |
5 |
|
|
|
|
|
|
|
|
|
|
pathway |
5 |
|
|
|
|
|
|
|
|
|
|
neurological |
5 |
|
|
|
|
|
|
|
|
|
|
record |
5 |
|
|
|
|
|
|
|
|
|
|
classification |
5 |
|
|
|
|
|
|
|
|
|
|
processing |
5 |
|
|
|
|
|
|
|
|
|
|
phenotypes |
5 |
|
|
|
|
|
|
|
|
|
|
validated |
5 |
|
|
|
|
|
|
|
|
|
|
prevention |
5 |
|
|
|
|
|
|
|
|
|
|
size |
5 |
|
|
|
|
|
|
|
|
|
|
achieved |
5 |
|
|
|
|
|
|
|
|
|
|
increasing |
5 |
|
|
|
|
|
|
|
|
|
|
gut |
5 |
|
|
|
|
|
|
|
|
|
|
activities |
5 |
|
|
|
|
|
|
|
|
|
|
aged |
5 |
|
|
|
|
|
|
|
|
|
|
older |
5 |
|
|
|
|
|
|
|
|
|
|
healthy |
5 |
|
|
|
|
|
|
|
|
|
|
superior |
5 |
|
|
|
|
|
|
|
|
|
|
side |
5 |
|
|
|
|
|
|
|
|
|
|
transcription |
5 |
|
|
|
|
|
|
|
|
|
|
detect |
5 |
|
|
|
|
|
|
|
|
|
|
each |
5 |
|
|
|
|
|
|
|
|
|
|
elucidate |
5 |
|
|
|
|
|
|
|
|
|
|
conformational |
5 |
|
|
|
|
|
|
|
|
|
|
aureus |
5 |
|
|
|
|
|
|
|
|
|
|
wild |
5 |
|
|
|
|
|
|
|
|
|
|
fold |
5 |
|
|
|
|
|
|
|
|
|
|
blocking |
5 |
|
|
|
|
|
|
|
|
|
|
finally |
5 |
|
|
|
|
|
|
|
|
|
|
particular |
5 |
|
|
|
|
|
|
|
|
|
|
interface |
5 |
|
|
|
|
|
|
|
|
|
|
cardiac |
5 |
|
|
|
|
|
|
|
|
|
|
pulmonary |
5 |
|
|
|
|
|
|
|
|
|
|
studying |
5 |
|
|
|
|
|
|
|
|
|
|
nps |
5 |
|
|
|
|
|
|
|
|
|
|
extraction |
5 |
|
|
|
|
|
|
|
|
|
|
assessment |
5 |
|
|
|
|
|
|
|
|
|
|
unknown |
5 |
|
|
|
|
|
|
|
|
|
|
quantitative |
5 |
|
|
|
|
|
|
|
|
|
|
arm |
5 |
|
|
|
|
|
|
|
|
|
|
received |
5 |
|
|
|
|
|
|
|
|
|
|
assess |
5 |
|
|
|
|
|
|
|
|
|
|
markers |
5 |
|
|
|
|
|
|
|
|
|
|
cycle |
5 |
|
|
|
|
|
|
|
|
|
|
intervention |
5 |
|
|
|
|
|
|
|
|
|
|
part |
5 |
|
|
|
|
|
|
|
|
|
|
biology |
5 |
|
|
|
|
|
|
|
|
|
|
injury |
5 |
|
|
|
|
|
|
|
|
|
|
utility |
5 |
|
|
|
|
|
|
|
|
|
|
pca |
5 |
|
|
|
|
|
|
|
|
|
|
product |
5 |
|
|
|
|
|
|
|
|
|
|
recurrent |
5 |
|
|
|
|
|
|
|
|
|
|
approved |
5 |
|
|
|
|
|
|
|
|
|
|
developing |
5 |
|
|
|
|
|
|
|
|
|
|
prediction |
5 |
|
|
|
|
|
|
|
|
|
|
rapid |
5 |
|
|
|
|
|
|
|
|
|
|
injection |
5 |
|
|
|
|
|
|
|
|
|
|
antagonists |
5 |
|
|
|
|
|
|
|
|
|
|
whole |
5 |
|
|
|
|
|
|
|
|
|
|
reduction |
5 |
|
|
|
|
|
|
|
|
|
|
co2 |
5 |
|
|
|
|
|
|
|
|
|
|
probe |
4 |
|
|
|
|
|
|
|
|
|
|
defects |
4 |
|
|
|
|
|
|
|
|
|
|
methodologies |
4 |
|
|
|
|
|
|
|
|
|
|
polymers |
4 |
|
|
|
|
|
|
|
|
|
|
bound |
4 |
|
|
|
|
|
|
|
|
|
|
details |
4 |
|
|
|
|
|
|
|
|
|
|
groups |
4 |
|
|
|
|
|
|
|
|
|
|
reduced |
4 |
|
|
|
|
|
|
|
|
|
|
extent |
4 |
|
|
|
|
|
|
|
|
|
|
transplantation |
4 |
|
|
|
|
|
|
|
|
|
|
living |
4 |
|
|
|
|
|
|
|
|
|
|
mir |
4 |
|
|
|
|
|
|
|
|
|
|
assay |
4 |
|
|
|
|
|
|
|
|
|
|
industry |
4 |
|
|
|
|
|
|
|
|
|
|
accurately |
4 |
|
|
|
|
|
|
|
|
|
|
efficiently |
4 |
|
|
|
|
|
|
|
|
|
|
r |
4 |
|
|
|
|
|
|
|
|
|
|
toxic |
4 |
|
|
|
|
|
|
|
|
|
|
exchange |
4 |
|
|
|
|
|
|
|
|
|
|
subsequent |
4 |
|
|
|
|
|
|
|
|
|
|
protective |
4 |
|
|
|
|
|
|
|
|
|
|
69 |
4 |
|
|
|
|
|
|
|
|
|
|
42 |
4 |
|
|
|
|
|
|
|
|
|
|
phenomenon |
4 |
|
|
|
|
|
|
|
|
|
|
clearly |
4 |
|
|
|
|
|
|
|
|
|
|
according |
4 |
|
|
|
|
|
|
|
|
|
|
presenting |
4 |
|
|
|
|
|
|
|
|
|
|
national |
4 |
|
|
|
|
|
|
|
|
|
|
commonly |
4 |
|
|
|
|
|
|
|
|
|
|
98 |
4 |
|
|
|
|
|
|
|
|
|
|
areas |
4 |
|
|
|
|
|
|
|
|
|
|
regulatory |
4 |
|
|
|
|
|
|
|
|
|
|
observed |
4 |
|
|
|
|
|
|
|
|
|
|
host |
4 |
|
|
|
|
|
|
|
|
|
|
fluorescence |
4 |
|
|
|
|
|
|
|
|
|
|
power |
4 |
|
|
|
|
|
|
|
|
|
|
signal |
4 |
|
|
|
|
|
|
|
|
|
|
provides |
4 |
|
|
|
|
|
|
|
|
|
|
catalyzed |
4 |
|
|
|
|
|
|
|
|
|
|
describe |
4 |
|
|
|
|
|
|
|
|
|
|
zikv |
4 |
|
|
|
|
|
|
|
|
|
|
quite |
4 |
|
|
|
|
|
|
|
|
|
|
34 |
4 |
|
|
|
|
|
|
|
|
|
|
19 |
4 |
|
|
|
|
|
|
|
|
|
|
fibrosis |
4 |
|
|
|
|
|
|
|
|
|
|
nmr |
4 |
|
|
|
|
|
|
|
|
|
|
analyzed |
4 |
|
|
|
|
|
|
|
|
|
|
walls |
4 |
|
|
|
|
|
|
|
|
|
|
play |
4 |
|
|
|
|
|
|
|
|
|
|
crucial |
4 |
|
|
|
|
|
|
|
|
|
|
collectively |
4 |
|
|
|
|
|
|
|
|
|
|
modulation |
4 |
|
|
|
|
|
|
|
|
|
|
neuronal |
4 |
|
|
|
|
|
|
|
|
|
|
down |
4 |
|
|
|
|
|
|
|
|
|
|
alzheimer |
4 |
|
|
|
|
|
|
|
|
|
|
il13 |
4 |
|
|
|
|
|
|
|
|
|
|
controls |
4 |
|
|
|
|
|
|
|
|
|
|
represents |
4 |
|
|
|
|
|
|
|
|
|
|
peanut |
4 |
|
|
|
|
|
|
|
|
|
|
suggests |
4 |
|
|
|
|
|
|
|
|
|
|
scale |
4 |
|
|
|
|
|
|
|
|
|
|
transgene |
4 |
|
|
|
|
|
|
|
|
|
|
editing |
4 |
|
|
|
|
|
|
|
|
|
|
oxide |
4 |
|
|
|
|
|
|
|
|
|
|
measurements |
4 |
|
|
|
|
|
|
|
|
|
|
severity |
4 |
|
|
|
|
|
|
|
|
|
|
prior |
4 |
|
|
|
|
|
|
|
|
|
|
maximum |
4 |
|
|
|
|
|
|
|
|
|
|
old |
4 |
|
|
|
|
|
|
|
|
|
|
followed |
4 |
|
|
|
|
|
|
|
|
|
|
significance |
4 |
|
|
|
|
|
|
|
|
|
|
establish |
4 |
|
|
|
|
|
|
|
|
|
|
stromal |
4 |
|
|
|
|
|
|
|
|
|
|
quantum |
4 |
|
|
|
|
|
|
|
|
|
|
pediatric |
4 |
|
|
|
|
|
|
|
|
|
|
syndrome |
4 |
|
|
|
|
|
|
|
|
|
|
affecting |
4 |
|
|
|
|
|
|
|
|
|
|
measures |
4 |
|
|
|
|
|
|
|
|
|
|
investigating |
4 |
|
|
|
|
|
|
|
|
|
|
iii |
4 |
|
|
|
|
|
|
|
|
|
|
collected |
4 |
|
|
|
|
|
|
|
|
|
|
probes |
4 |
|
|
|
|
|
|
|
|
|
|
rituximab |
4 |
|
|
|
|
|
|
|
|
|
|
complement |
4 |
|
|
|
|
|
|
|
|
|
|
creating |
4 |
|
|
|
|
|
|
|
|
|
|
enzyme |
4 |
|
|
|
|
|
|
|
|
|
|
events |
4 |
|
|
|
|
|
|
|
|
|
|
nor |
4 |
|
|
|
|
|
|
|
|
|
|
maintaining |
4 |
|
|
|
|
|
|
|
|
|
|
132 |
4 |
|
|
|
|
|
|
|
|
|
|
obligate |
4 |
|
|
|
|
|
|
|
|
|
|
c9orf72 |
4 |
|
|
|
|
|
|
|
|
|
|
carriers |
4 |
|
|
|
|
|
|
|
|
|
|
affected |
4 |
|
|
|
|
|
|
|
|
|
|
existing |
4 |
|
|
|
|
|
|
|
|
|
|
device |
4 |
|
|
|
|
|
|
|
|
|
|
spatial |
4 |
|
|
|
|
|
|
|
|
|
|
advantageous |
4 |
|
|
|
|
|
|
|
|
|
|
resolving |
4 |
|
|
|
|
|
|
|
|
|
|
autoimmune |
4 |
|
|
|
|
|
|
|
|
|
|
61 |
4 |
|
|
|
|
|
|
|
|
|
|
masses |
4 |
|
|
|
|
|
|
|
|
|
|
assessed |
4 |
|
|
|
|
|
|
|
|
|
|
ablation |
4 |
|
|
|
|
|
|
|
|
|
|
support |
4 |
|
|
|
|
|
|
|
|
|
|
mutant |
4 |
|
|
|
|
|
|
|
|
|
|
fluorescent |
4 |
|
|
|
|
|
|
|
|
|
|
architecture |
4 |
|
|
|
|
|
|
|
|
|
|
though |
4 |
|
|
|
|
|
|
|
|
|
|
hole |
4 |
|
|
|
|
|
|
|
|
|
|
storage |
4 |
|
|
|
|
|
|
|
|
|
|
78 |
4 |
|
|
|
|
|
|
|
|
|
|
chemotherapy |
4 |
|
|
|
|
|
|
|
|
|
|
diagnosed |
4 |
|
|
|
|
|
|
|
|
|
|
mutated |
4 |
|
|
|
|
|
|
|
|
|
|
gap |
4 |
|
|
|
|
|
|
|
|
|
|
good |
4 |
|
|
|
|
|
|
|
|
|
|
belatacept |
4 |
|
|
|
|
|
|
|
|
|
|
spin |
4 |
|
|
|
|
|
|
|
|
|
|
physics |
4 |
|
|
|
|
|
|
|
|
|
|
carbon |
4 |
|
|
|
|
|
|
|
|
|
|
simultaneously |
4 |
|
|
|
|
|
|
|
|
|
|
caused |
4 |
|
|
|
|
|
|
|
|
|
|
evolution |
4 |
|
|
|
|
|
|
|
|
|
|
four |
4 |
|
|
|
|
|
|
|
|
|
|
leptomeningeal |
4 |
|
|
|
|
|
|
|
|
|
|
forms |
4 |
|
|
|
|
|
|
|
|
|
|
rp |
4 |
|
|
|
|
|
|
|
|
|
|
23 |
4 |
|
|
|
|
|
|
|
|
|
|
investigation |
4 |
|
|
|
|
|
|
|
|
|
|
catalytic |
4 |
|
|
|
|
|
|
|
|
|
|
core |
4 |
|
|
|
|
|
|
|
|
|
|
oxidation |
4 |
|
|
|
|
|
|
|
|
|
|
olive |
4 |
|
|
|
|
|
|
|
|
|
|
oil |
4 |
|
|
|
|
|
|
|
|
|
|
institutional |
4 |
|
|
|
|
|
|
|
|
|
|
database |
4 |
|
|
|
|
|
|
|
|
|
|
retrospectively |
4 |
|
|
|
|
|
|
|
|
|
|
hematopoietic |
4 |
|
|
|
|
|
|
|
|
|
|
insulin |
4 |
|
|
|
|
|
|
|
|
|
|
pancreatic |
4 |
|
|
|
|
|
|
|
|
|
|
protocols |
4 |
|
|
|
|
|
|
|
|
|
|
labeled |
4 |
|
|
|
|
|
|
|
|
|
|
practical |
4 |
|
|
|
|
|
|
|
|
|
|
formulations |
4 |
|
|
|
|
|
|
|
|
|
|
spectrum |
4 |
|
|
|
|
|
|
|
|
|
|
phi |
4 |
|
|
|
|
|
|
|
|
|
|
images |
4 |
|
|
|
|
|
|
|
|
|
|
benign |
4 |
|
|
|
|
|
|
|
|
|
|
malignant |
4 |
|
|
|
|
|
|
|
|
|
|
thought |
4 |
|
|
|
|
|
|
|
|
|
|
broad |
4 |
|
|
|
|
|
|
|
|
|
|
set |
4 |
|
|
|
|
|
|
|
|
|
|
learning |
4 |
|
|
|
|
|
|
|
|
|
|
estimation |
4 |
|
|
|
|
|
|
|
|
|
|
biomarker |
4 |
|
|
|
|
|
|
|
|
|
|
predict |
4 |
|
|
|
|
|
|
|
|
|
|
combinatorial |
4 |
|
|
|
|
|
|
|
|
|
|
short |
4 |
|
|
|
|
|
|
|
|
|
|
evaluate |
4 |
|
|
|
|
|
|
|
|
|
|
ims |
4 |
|
|
|
|
|
|
|
|
|
|
implementation |
4 |
|
|
|
|
|
|
|
|
|
|
means |
4 |
|
|
|
|
|
|
|
|
|
|
layer |
4 |
|
|
|
|
|
|
|
|
|
|
cognitive |
4 |
|
|
|
|
|
|
|
|
|
|
composition |
4 |
|
|
|
|
|
|
|
|
|
|
antibacterial |
4 |
|
|
|
|
|
|
|
|
|
|
facilitate |
4 |
|
|
|
|
|
|
|
|
|
|
pivotal |
4 |
|
|
|
|
|
|
|
|
|
|
regulation |
4 |
|
|
|
|
|
|
|
|
|
|
translational |
4 |
|
|
|
|
|
|
|
|
|
|
recruited |
4 |
|
|
|
|
|
|
|
|
|
|
lack |
4 |
|
|
|
|
|
|
|
|
|
|
y |
4 |
|
|
|
|
|
|
|
|
|
|
performing |
4 |
|
|
|
|
|
|
|
|
|
|
feedback |
4 |
|
|
|
|
|
|
|
|
|
|
traditional |
4 |
|
|
|
|
|
|
|
|
|
|
computational |
4 |
|
|
|
|
|
|
|
|
|
|
profiling |
4 |
|
|
|
|
|
|
|
|
|
|
reactive |
4 |
|
|
|
|
|
|
|
|
|
|
community |
4 |
|
|
|
|
|
|
|
|
|
|
stimulation |
4 |
|
|
|
|
|
|
|
|
|
|
previously |
4 |
|
|
|
|
|
|
|
|
|
|
competing |
4 |
|
|
|
|
|
|
|
|
|
|
produced |
4 |
|
|
|
|
|
|
|
|
|
|
inclusion |
4 |
|
|
|
|
|
|
|
|
|
|
extracts |
4 |
|
|
|
|
|
|
|
|
|
|
gram |
4 |
|
|
|
|
|
|
|
|
|
|
increase |
4 |
|
|
|
|
|
|
|
|
|
|
local |
4 |
|
|
|
|
|
|
|
|
|
|
relatively |
4 |
|
|
|
|
|
|
|
|
|
|
help |
4 |
|
|
|
|
|
|
|
|
|
|
mouse |
4 |
|
|
|
|
|
|
|
|
|
|
elements |
4 |
|
|
|
|
|
|
|
|
|
|
topological |
4 |
|
|
|
|
|
|
|
|
|
|
simultaneous |
4 |
|
|
|
|
|
|
|
|
|
|
currently |
4 |
|
|
|
|
|
|
|
|
|
|
previous |
4 |
|
|
|
|
|
|
|
|
|
|
include |
4 |
|
|
|
|
|
|
|
|
|
|
degradation |
4 |
|
|
|
|
|
|
|
|
|
|
scanning |
4 |
|
|
|
|
|
|
|
|
|
|
never |
4 |
|
|
|
|
|
|
|
|
|
|
definitively |
4 |
|
|
|
|
|
|
|
|
|
|
orthogonal |
4 |
|
|
|
|
|
|
|
|
|
|
observations |
4 |
|
|
|
|
|
|
|
|
|
|
engineered |
4 |
|
|
|
|
|
|
|
|
|
|
concentrations |
4 |
|
|
|
|
|
|
|
|
|
|
attempts |
4 |
|
|
|
|
|
|
|
|
|
|
intact |
4 |
|
|
|
|
|
|
|
|
|
|
authors |
4 |
|
|
|
|
|
|
|
|
|
|
vectors |
4 |
|
|
|
|
|
|
|
|
|
|
variant |
4 |
|
|
|
|
|
|
|
|
|
|
knowledge |
4 |
|
|
|
|
|
|
|
|
|
|
remain |
4 |
|
|
|
|
|
|
|
|
|
|
status |
4 |
|
|
|
|
|
|
|
|
|
|
inhibitor |
4 |
|
|
|
|
|
|
|
|
|
|
microwave |
4 |
|
|
|
|
|
|
|
|
|
|
march |
4 |
|
|
|
|
|
|
|
|
|
|
accuracy |
4 |
|
|
|
|
|
|
|
|
|
|
mode |
4 |
|
|
|
|
|
|
|
|
|
|
cross |
4 |
|
|
|
|
|
|
|
|
|
|
genomic |
4 |
|
|
|
|
|
|
|
|
|
|
almost |
4 |
|
|
|
|
|
|
|
|
|
|
physiological |
4 |
|
|
|
|
|
|
|
|
|
|
growing |
4 |
|
|
|
|
|
|
|
|
|
|
protocol |
4 |
|
|
|
|
|
|
|
|
|
|
become |
4 |
|
|
|
|
|
|
|
|
|
|
51 |
4 |
|
|
|
|
|
|
|
|
|
|
microenvironment |
4 |
|
|
|
|
|
|
|
|
|
|
particle |
4 |
|
|
|
|
|
|
|
|
|
|
provided |
4 |
|
|
|
|
|
|
|
|
|
|
promoted |
4 |
|
|
|
|
|
|
|
|
|
|
networks |
4 |
|
|
|
|
|
|
|
|
|
|
tumour |
4 |
|
|
|
|
|
|
|
|
|
|
providing |
4 |
|
|
|
|
|
|
|
|
|
|
endophthalmitis |
4 |
|
|
|
|
|
|
|
|
|
|
horizontal |
4 |
|
|
|
|
|
|
|
|
|
|
proportion |
4 |
|
|
|
|
|
|
|
|
|
|
severe |
4 |
|
|
|
|
|
|
|
|
|
|
density |
4 |
|
|
|
|
|
|
|
|
|
|
acr |
4 |
|
|
|
|
|
|
|
|
|
|
characteristic |
4 |
|
|
|
|
|
|
|
|
|
|
day |
4 |
|
|
|
|
|
|
|
|
|
|
prevent |
4 |
|
|
|
|
|
|
|
|
|
|
fungal |
4 |
|
|
|
|
|
|
|
|
|
|
solvent |
4 |
|
|
|
|
|
|
|
|
|
|
procedure |
4 |
|
|
|
|
|
|
|
|
|
|
ml |
4 |
|
|
|
|
|
|
|
|
|
|
readily |
4 |
|
|
|
|
|
|
|
|
|
|
adult |
4 |
|
|
|
|
|
|
|
|
|
|
changing |
4 |
|
|
|
|
|
|
|
|
|
|
simulations |
4 |
|
|
|
|
|
|
|
|
|
|
platforms |
4 |
|
|
|
|
|
|
|
|
|
|
robustness |
4 |
|
|
|
|
|
|
|
|
|
|
margins |
4 |
|
|
|
|
|
|
|
|
|
|
respective |
4 |
|
|
|
|
|
|
|
|
|
|
honey |
4 |
|
|
|
|
|
|
|
|
|
|
immunotherapy |
4 |
|
|
|
|
|
|
|
|
|
|
occurrence |
4 |
|
|
|
|
|
|
|
|
|
|
any |
4 |
|
|
|
|
|
|
|
|
|
|
exome |
4 |
|
|
|
|
|
|
|
|
|
|
aspects |
4 |
|
|
|
|
|
|
|
|
|
|
practice |
4 |
|
|
|
|
|
|
|
|
|
|
monitoring |
4 |
|
|
|
|
|
|
|
|
|
|
independent |
4 |
|
|
|
|
|
|
|
|
|
|
min |
4 |
|
|
|
|
|
|
|
|
|
|
feature |
4 |
|
|
|
|
|
|
|
|
|
|
settings |
4 |
|
|
|
|
|
|
|
|
|
|
radiological |
4 |
|
|
|
|
|
|
|
|
|
|
worsening |
4 |
|
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。